{"schema_version":"secwatch.filing_event.v1","accession":"0001376339-26-000032","form_type":"8-K","ticker":"MDXG","cik":"0001376339","company_name":"MIMEDX GROUP, INC.","filed_at":"2026-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.210090+00:00","generated_at":"2026-05-15T01:39:19.023984+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"MiMedx Q1 net sales $59M (-33% YoY), loss $11M; cuts FY guidance to $260-290M","bullets":["Q1 net sales $59M, down 33% YoY from $88M; net loss $11M vs net income $7M a year ago.","Surgical product sales up 13% YoY; Wound sales down 60% due to Medicare payment cap per cm².","Gross margin fell to 71% from 81% on pricing pressure and unfavorable product mix.","FY2026 net sales guidance lowered to $260-290M; Adjusted EBITDA expected approximately breakeven.","Company plans $40M annualized cost savings; CEO targets return to profitability in H2 and double-digit growth in 2027."],"urls":{"canonical":"https://secwatch.observer/filing/0001376339-26-000032","json":"https://secwatch.observer/filing/0001376339-26-000032.json","markdown":"https://secwatch.observer/filing/0001376339-26-000032.md","text":"https://secwatch.observer/filing/0001376339-26-000032.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1376339/000137633926000032/0001376339-26-000032-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1376339/000137633926000032/mdxg-20260429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T01:39:19.023984+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d04833938d1a04cd3164f7b941dee3af998819c5","claim":"MIMEDX GROUP, INC. reported first quarter 2026 results: revenue $59 million, net income $11 million. Guidance lowered.","evidence_excerpt":"MIMEDX Announces First Quarter 2026 Operating & Financial Results Reports First Quarter Net Sales of $59 Million Revises 2026 Net Sales and Adjusted EBITDA Expectations","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1376339/000137633926000032/0001376339-26-000032-index.htm","confidence":0.92,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter 2026"},{"label":"Revenue","value":"$59 million"},{"label":"Net income","value":"$11 million"},{"label":"Guidance","value":"lowered"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}